Five things for pharma marketers to know: Thursday, July 7, 2016

A recent campaign for EpiPen focused on preparation.

1. As prices of Mylan's EpiPens have increased, some emergency responders and families are relying on less expensive manual syringes rather than auto-injectors. There were about 3.6 million prescriptions for EpiPens in 2015. (Stat)

2. States that passed medical marijuana laws have seen a drop in drugs prescribed for nine common medical conditions. In these states, Medicare Part D spending was reduced by $165.2 million in 2013. (Health Affairs)

3. Pfizer and Merck KGaA started a late-stage trial of an experimental immuno-oncology drug called avelumab, that is used in combination with the standard treatment for ovarian cancer. (Reuters)

4. Xtandi, an expensive prostate cancer drug manufactured by Medivation, is at the center of a bidding war among pharma companies to acquire Medivation. The drug costs $129,000 per year. (LAT)

5. The digital health market received $3.9 billion in funding in the first half of 2016, up from $2.9 billion in the same period a year ago. (StartUp Health)